Studies examining body composition changes during GLP-1 therapy, including the STEP trials (semaglutide) and SURMOUNT-1 (tirzepatide), have demonstrated that approximately 2540% of total weight lost may come from lean body mass, including skeletal muscle, rather than exclusively from fat mass
Switching would require a new titration period (starting at 2mg and escalating over 812 weeks to target dose), may temporarily restart GI side effects, and would need new insurance prior authorization
Remember, its not about depriving yourself of the foods you love, its about finding healthier alternatives that you enjoy just as much
Most donors on stable doses have no timing restrictions
Como outros benefcios para praticantes de atividade fsica, ainda existe a diminuio da fadiga e a reduo do dano tecidual depois do treino